Form 4: Avidity Biosciences Chief Technical Officer Acquires Shares and Stock Options

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, acquired 40,000 shares of common stock and 80,000 stock options on January 6, 2025.

Summary

• Charles Calderaro III, Chief Technical Officer of Avidity Biosciences, acquired 40,000 shares of common stock and 80,000 stock options on January 6, 2025.
• The 40,000 shares were acquired as restricted stock units (RSUs), which will vest in four equal installments on the first four anniversaries of January 6, 2025, contingent on continuous service.
• The 80,000 stock options vest with 1/4 of the shares vesting on the first anniversary of January 6, 2025, and the remaining 1/48 vesting monthly thereafter.
• The stock options have an exercise price of $31.42 and expire on January 5, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive as it aligns executive interests with company performance. There are no negative implications.

Positives

• The acquisition of shares and options by a key executive suggests confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options aligns the executive's interests with the long-term success of the company.

Risks

• The vesting of the RSUs and stock options is contingent on the executive's continued employment with the company, which could be a risk if the executive leaves before full vesting.

Future Outlook

The vesting of the RSUs and stock options is tied to the executive's continued service, suggesting a long-term commitment to the company.

Industry Context

This type of equity-based compensation is common in the biotechnology industry to attract and retain key talent and align their interests with shareholders.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages in the biotech industry.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals also use similar equity-based incentives to align executive interests with company performance.
• The vesting schedules described are typical for these types of grants, with vesting periods ranging from 3 to 5 years.

Stakeholder Impact

• The acquisition of shares and options by a key executive could be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Avidity Biosciences, stock options, restricted stock units, executive compensation, insider trading, RNA, Charles Calderaro III